Literature DB >> 35001407

Strategies for designing proteolysis targeting chimaeras (PROTACs).

Shipeng He1, Guoqiang Dong2, Junfei Cheng2, Ying Wu2,3, Chunquan Sheng2.   

Abstract

Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique for new drug discovery and development. Currently, the largest challenge in the molecular design and drug development of PROTACs is efficient identification of potent and drug-like degraders. This review aims to comprehensively summarize and analyse state-of-the-art methods and strategies in the design of PROTACs. We provide a detailed illustration of the general principles and tactics for designing potent PROTACs, highlight representative case studies, and discuss the advantages and limitations of these strategies. Particularly, structure-based rational PROTAC design and emerging new types of PROTACs (e.g., homo-PROTACs, multitargeting PROTACs, photo-control PROTACs and PROTAC-based conjugates) will be focused on.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  E3 ligase ligands; design strategy; drug-likeness; proteolysis targeting chimaeras; targeted protein degradation

Mesh:

Year:  2022        PMID: 35001407     DOI: 10.1002/med.21877

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  6 in total

1.  PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.

Authors:  Xin Han; Wenyi Wei; Yi Sun
Journal:  Acta Mater Med       Date:  2022-05-31

Review 2.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 3.  Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.

Authors:  Chao Wang; Yujing Zhang; Tingting Zhang; Lingyu Shi; Zhongmin Geng; Dongming Xing
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 4.  Small-Molecule PROTACs for Cancer Immunotherapy.

Authors:  Zefan Liu; Yajun Zhang; Yucheng Xiang; Xin Kang
Journal:  Molecules       Date:  2022-08-25       Impact factor: 4.927

5.  PROTACs bearing piperazine-containing linkers: what effect on their protonation state?

Authors:  Jenny Desantis; Andrea Mammoli; Michela Eleuteri; Alice Coletti; Federico Croci; Antonio Macchiarulo; Laura Goracci
Journal:  RSC Adv       Date:  2022-08-09       Impact factor: 4.036

6.  Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression.

Authors:  Si Chen; Xiang Li; Yinghua Li; Xing Yuan; Chenchen Geng; Songyan Gao; Jinyang Li; Bohan Ma; Zhe Wang; Wuyuan Lu; Hong-Gang Hu
Journal:  Theranostics       Date:  2022-09-11       Impact factor: 11.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.